Intellicheck to Announce Fourth Quarter and Full Year 2024 Financial Results
Financial Results Conference Call March 20 at 4:30 p.m. ET/1:30 p.m. PT MELVILLE, N.Y.–(BUSINESS WIRE)–$IDN #InvestorRelations—Intellicheck, Inc.... Read more.
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
First patient enrolled in ECLIPSE 1 Phase 3 clinical trial evaluating combination of tobevibart and elebsiran for chronic suppressive treatment ECLIPSE program designed... Read more.
Japanese Automotive Tier1s Propel Forward with Enhanced Co-operation and Emerging Technologies – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Japanese Automotive Tier1s’ Advanced Technologies and Products Research Report, 2024-2025” report has been... Read more.
Iochpe-Maxion Names Pieter Klinkers President and CEO
SÃO PAULO–(BUSINESS WIRE)–Iochpe-Maxion SA, a world leader in the production of automotive wheels and a leading producer of automotive structural components... Read more.
Specialist Music Investment Platform Round Hill Music Further Strengthens Executive Team With Two Strategic Hires
NEW YORK–(BUSINESS WIRE)–Round Hill Music Royalty Partners LP (“Round Hill Music” or the “Company”), the pioneering private equity platform founded... Read more.
Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
— Key Data Readouts from Sentinel Participant in RLYB212 Phase 2 Clinical Trial Expected in 2Q 2025 and 3Q 2025 — — Initiation of RLYB116 Confirmatory PK/PD... Read more.
Cherry Hill Mortgage Investment Corporation Announces Common and Preferred Dividends for the First Quarter 2025
TINTON FALLS, N.J.–(BUSINESS WIRE)–Cherry Hill Mortgage Investment Corporation (NYSE: CHMI) today announced that its Board of Directors declared a dividend... Read more.
43% of Healthcare Email Breaches Tied to Microsoft 365—New Report Uncovers the Major Cybersecurity Gaps
SAN FRANCISCO–(BUSINESS WIRE)–A new report analyzing 180 healthcare email breaches from January 1, 2024, to January 31, 2025 reveals widespread cybersecurity... Read more.
Myrobalan Therapeutics Awarded a Grant from the National Multiple Sclerosis Society to Advance Development of MRO-002 in Multiple Sclerosis
Myrobalan to receive over $850,000 in funding to advance the development of MRO-002, a novel GPR17 antagonist, with the potential to promote remyelination in progressive... Read more.
Epirium Bio to Present MF-300 Preclinical Data at the International Conference on Frailty and Sarcopenia Research
Data show MF-300, a First-in-Class 15-PGDH Enzyme Inhibitor, Improves Aged Muscle Quality and Accelerates Recovery of Muscle Function Following Nerve Injury SAN... Read more.